Researchers work to block harmful behavior of key Alzheimer's enzyme

February 25, 2016, Cell Press
This visual abstract depicts how Ben Halima et al. demonstrate the feasibility of designing drugs targeting the Alzheimer-related enzyme BACE1 without affecting its physiological function. Using structural, biochemical, and cellular approaches, they show that BACE1 inhibitors can be designed to specifically inhibit its disease-causing activity, enhancing their potential as therapeutics without undesired side effects. Credit: Ben Halima et al./Cell Reports 2016

Enzymes rarely have one job. So, attempts to shut down the enzyme that causes the hallmarks of Alzheimer's disease often mean side effects, because these therapies prevent the enzyme from carrying out many other functions. A study appearing February 25 in Cell Reports presents a new therapeutic strategy: blocking the most harmful behavior enzyme while allowing it to work normally otherwise. This potential approach now needs to be further developed and tested in pre-clinical trials.

In the brains of patients with Alzheimer's disease (AD), amyloid precursor protein is broken apart, and the resulting fragments—β-amyloid peptides, or Aβ peptides—aggregate to form plaques. Aβ peptides are produced by the action of two enzymes called beta- and gamma-secretases. Inhibiting either of these enzymes would block the production of toxic Aβ peptides; however, attempts to inhibit gamma-secretase caused problems in clinical trials because the also cleaves more than 20 other proteins important for normal physiology. β-secretase is now considered an alternative therapeutic target for AD, and a wide variety of inhibitors have been developed; however, β-secretase also cleaves several other proteins with normal functions in the body.

In their latest research, Lawrence Rajendran, of the University of Zurich in Switzerland, and his colleagues discovered that, unlike non-amyloid proteins, the Alzheimer's-associated amyloid is cleaved by β-secretase in membrane-bound compartments inside cells, called endosomes. Exploiting this compartmentalization, the team developed an endosomally-targeted β-secretase inhibitor that specifically blocked cleavage of but not non-amyloid proteins. This is the first time such specificity has been achieved, and it thus provides a potentially promising way to treat AD without causing major side effects.

"The current β-secretase inhibitors inhibit both the Alzheimer's disease process and physiologically relevant processes, and this would be a major problem, similar to the gamma-secretase inhibitors that failed in the clinic; however, with our strategy, we now can specifically inhibit the Alzheimer's process thereby avoiding any side effects," says Rajendran. He and his team plan to develop this inhibitor further and test it in .

Explore further: New therapeutic target discovered for Alzheimer's disease

More information: Cell Reports, Ben Halima et al.: "Specific Inhibition of β -Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein" dx.doi.org/10.1016/j.celrep.2016.01.076

Related Stories

New therapeutic target discovered for Alzheimer's disease

March 18, 2014
A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene ...

Overlooked for 30 years: Novel peptide plays role in Alzheimer's disease

August 31, 2015
A team led by Christian Haass has identified a novel peptide that plays a role in Alzheimer's disease: The previously overlooked eta-amyloid interferes with neuronal function and may antogonize beta-amyloid – a finding ...

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011
Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

New drugs to find the right target to fight Alzheimer's disease

August 2, 2013
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests ...

Molecular modeling of novel potent agents for treating Alzheimer's disease

June 11, 2015
Alzheimer's disease (AD), a severe form of dementia among aged individuals, is caused by accumulation of amyloid-beta (Aβ) peptides in the brain. Numerous types of agents have been developed to suppress the production of ...

Recommended for you

Genes linked to Alzheimer's contribute to damage in different ways

June 12, 2018
Multiple genes are implicated in Alzheimer's disease. Some are linked to early-onset Alzheimer's, a condition that develops in one's 30s, 40s and 50s, while others are associated with the more common late-onset form of the ...

Researchers reverse cognitive impairments in mice with dementia

June 8, 2018
Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research. A lack of knowledge about cellular pathways critical to the development of dementia, however, has stood in the ...

As mystery deepens over the cause of Alzheimer's, researchers seek new answers

June 6, 2018
For more than 20 years, much of the leading research on Alzheimer's disease has been guided by the "amyloid hypothesis."

Research reveals how Tau aggregates can contribute to cell death in Alzheimer's disease

June 5, 2018
New evidence suggests a mechanism by which progressive accumulation of Tau protein in brain cells may lead to Alzheimer's disease. Scientists studied more than 600 human brains and fruit fly models of Alzheimer's disease ...

How does alcohol influence the development of Alzheimer's disease?

June 4, 2018
Research from the University of Illinois at Chicago has found that some of the genes affected by alcohol and inflammation are also implicated in processes that clear amyloid beta—the protein that forms globs of plaques ...

Dementia patients could remain at home longer thanks to ground breaking technology

June 4, 2018
Innovative new technology will enable people with dementia to receive round the clock observation and live independently in their own homes, a new study in the Journal PLOS One reports.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.